This research grant supports the careers of young investigators interested in pulmonary arterial hypertension (PAH) research. Each year, PHA grants one award to a promising researcher who is likely to make a strong, sustained impact in PAH research.
Proposals should examine the pathophysiology of PAH to clarify mechanistic pathways and identify new therapeutic targets or biomarkers in adult or pediatric pulmonary hypertension (PH). The project potentially should apply to human pulmonary vascular diseases.
PHA encourages investigators to connect through its professional network, PH Clinicians and Researchers, during their research.
Applicants may request up to $40,000 a year for two years. The funds can cover salaries, supplies or a combination of the two. Indirect costs won’t be paid to sponsoring institutions.
Deadline: Apply by 5 p.m. ET Oct. 1, 2020. Review the policies and guidelines for eligibility and submission instructions.
Sponsorship support provided by Actelion Pharmaceuticals US Inc. through a partnership with PHA.
Questions? Contact us.